La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Babcock & Wilcox Enterprises, Inc. 8.125% Senior Notes due 2026 a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Babcock & Wilcox Enterprises, Inc. 8.125% Senior Notes due 2026..

Babcock & Wilcox Enterprises, Inc. 8.125% Senior Notes due 2026 (NYSE:BWSN) Azioni, Catena delle Opzioni

Babcock & Wilcox Enterprises, Inc. 8.125% Senior Notes due 2026

Goldman Sachs analyst Kate McShane maintains Five Below (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIVE#NASDAQ">FIVE</a>) with a Buy and raises the price target from $94 to $107.

News

Price Target

Analyst Ratings

FIVE

Goldman Sachs Maintains Buy on Five Below, Raises Price Target to $107

Goldman Sachs analyst Will Nance maintains Fiserv (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FI#NYSE">FI</a>) with a Buy and lowers the price target from $223 to $194.

Goldman Sachs Maintains Buy on Fiserv, Lowers Price Target to $194

RBC Capital analyst Gerard Cassidy reiterates M&amp;T Bank (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTB#NYSE">MTB</a>) with a Outperform and maintains $200 price target.

Reiteration

RBC Capital Reiterates Outperform on M&T Bank, Maintains $200 Price Target

Goldman Sachs analyst Brian Lee maintains First Solar (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>) with a Buy and raises the price target from $204 to $255.

FSLR

Goldman Sachs Maintains Buy on First Solar, Raises Price Target to $255

A Netflix Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) analyst is downgrading shares of the streaming giant with the stock near all-time highs following <a href="https://www.benzinga.com/general/entertainment/25/04/44877995/netflix-crushes-q1-says-its-working-hard-to-improve-and-expand-its-offering">first-quarter financial results.</a>
The Netflix Analyst: JPMorgan analyst Doug Anmuth downgraded Netflix stock from Overweight to Neutral and raised the price target from $1,150 to $1,220.
Read Also: <a href="https://www.benzinga.com/general/entertainment/25/05/45445251/netflixs-ad-tier-now-boasts-94m-users-fueling-stocks-rise-to-record-highs">Netflix&#8217;s Ad-Tier Now Boasts 94M Users, Fueling Stock&#8217;s Rise To Record Highs</a>
The Analyst Takeaways: With Netflix stock gaining significantly over the last year, the risk/reward in shares could be more balanced now, Anmuth said in a new investor note.
"To be clear, there's no change to our long-term bullish view on NFLX's streaming leadership position and the company's potential to effectively become global TV over time," Anmuth said.
The analyst said Netflix upside may already be factored into guidance and the summer months are typically slower for the streaming company.
"If tariff &amp; macro concerns continue to ease, we would expect rotation into other Internet names and parts of the market that have been more vulnerable &amp; pressured."
Anmuth recognizes that the downgrade could end up being wrong with Netflix having a strong slate of content for the back half of 2025. The analyst also said Netflix has several drivers, such as pricing power and advertising strength, that could make the 2026 and 2027 estimates higher.
Among the titles coming in the second half of 2025 include the return of the company's three most popular series of all time with new seasons of "Squid Game," "Stranger Things" and "Wednesday."
The analyst said Netflix stock deserves a premium, but investors may have too high of expectations for the second half of 2025.
"Since October 2022, NFLX shares have appreciated nearly 400% — or 5x — compared to the SPX up 60%. We move to the sidelines."
Long-term, Anmuth sees Netflix as one of the leaders in the disruption of linear television.
"With 300M+ global subs, Netflix has a strong leadership position in a rationalizing streaming industry and we expect NFLX to benefit."
NFLX Price Action: Netflix stock is down 0.65% to $1,183.80 on Monday versus a 52-week trading range of $588.43 to $1,196.50. Netflix stock is up 33.9% year-to-date in 2025 and up over 85% in the last year.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/general/entertainment/25/05/45200209/exclusive-netflix-customers-excited-for-original-movies-squid-game-stranger-things-nfl-60-say-this-tops-2025-must-watch-list">EXCLUSIVE: Netflix Customers Excited For Original Movies, &#8216;Squid Game,&#8217; &#8216;Stranger Things,&#8217; NFL: 60% Say This Tops 2025 Must-Watch List</a></li>
</ul>
Photo: marekfromrzeszow via Shutterstock

Analyst Color

Entertainment

Downgrades

Media

Trading Ideas

NFLX

Netflix Stock Gets Downgrade With Shares Up 400% In Three Years: 'Expect Rotation Into Other Internet Names'

Goldman Sachs analyst Kate McShane maintains Dollar General (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DG#NYSE">DG</a>) with a Buy and raises the price target from $85 to $96.

Goldman Sachs Maintains Buy on Dollar General, Raises Price Target to $96

Goldman Sachs analyst Brian Lee maintains Array Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARRY#NASDAQ">ARRY</a>) with a Buy and raises the price target from $9 to $11.

ARRY

Goldman Sachs Maintains Buy on Array Technologies, Raises Price Target to $11

RBC Capital analyst Michael Carroll reiterates LTC Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LTC#NYSE">LTC</a>) with a Sector Perform and maintains $36 price target.

RBC Capital Reiterates Sector Perform on LTC Properties, Maintains $36 Price Target

GFL Environmental (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GFL#NYSE">GFL</a>) has outperformed the market over the past 5 years by 7.76% on an annualized basis producing an average annual return of 22.75%. Currently, GFL Environmental has a market capitalization of $18.08 billion. 
Buying $100 In GFL: If an investor had bought $100 of GFL stock 5 years ago, it would be worth $285.80 today based on a price of $49.30 for GFL at the time of writing.
<h3>GFL Environmental's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747673112_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $100 In This Stock 5 Years Ago, You Would Have This Much Today

RBC Capital analyst Kenneth Lee reiterates Kayne Anderson BDC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KBDC#NYSE">KBDC</a>) with a Outperform and maintains $17 price target.

KBDC

RBC Capital Reiterates Outperform on Kayne Anderson BDC, Maintains $17 Price Target

RBC Capital analyst Ben Hendrix reiterates GoHealth (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOCO#NASDAQ">GOCO</a>) with a Sector Perform and maintains $18 price target.

GOCO

RBC Capital Reiterates Sector Perform on GoHealth, Maintains $18 Price Target

- For each 5-mg/dL increase in serum TTR level within 28 days of starting treatment, the relative risk reduction of mortality was up to 31.6% through Month 30, confirming the hypothesis that ever better levels of stabilization achieved by treatment with acoramidis, a near-complete (≥90%) TTR stabilizer, lead to ever better clinical outcomes
- ATTRibute-CM is the only study to demonstrate a direct association between a prompt, sustained increase in serum TTR and survival in patients with ATTR-CM
- The open-label extension data for all ATTRibute-CM participants at Month 42 showed that rapid, sustained TTR stabilization from acoramidis demonstrated statistically significant reductions in ACM and CVH (including urgent outpatient treatment for heart failure exacerbations)
- In the ATTRibute-CM study, acoramidis demonstrated the most rapid benefit seen in any Phase 3 study of ATTR-CM to date in both ATTRv-CM and ATTRwt-CM patients:
- In as few as 3 months, the time to first event (ACM or CVH) durably separated relative&nbsp;to placebo - A 42% reduction in composite ACM and recurrent CVH events relative to placebo at Month 30 - A 50% reduction in the cumulative frequency of CVH events relative to placebo at Month 30
- Acoramidis is approved as Attruby&#x2122; by the U.S. FDA and is approved as BEYONTTRA&#xAE; by the European Commission, the Japanese Pharmaceuticals and Medical Devices Agency, and the UK Medicines and Healthcare Products Regulatory Agency
PALO ALTO, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBIO#NASDAQ">BBIO</a>) ("BridgeBio" or the "Company"),&nbsp;a new type of biopharmaceutical company focused on genetic diseases, published data showing that an early, sustained increase in serum transthyretin (TTR) levels predicted improved survival in ATTRibute-CM, its Phase 3 trial of acoramidis in transthyretin amyloid cardiomyopathy (ATTR-CM). These findings were published in Journal of the American College of Cardiology (JACC) in the Special Focus Issue: Amyloid. Acoramidis is a selective, small molecule, orally administered, near-complete (≥90%) TTR stabilizer. These findings further support the thesis that ever better increases in serum TTR lead to ever better clinical outcomes and that early elevations in serum TTR are an important prognostic marker to inform treatment selection.

BBIO

Bridgebio Pharma Publishes Data Showing Sustained Increase In Serum TTR Levels Predicted Improved Survival In ATTRibute-CM, Phase 3 Trial Of ATTR-CM

<a href="https://www.dell.com/en-us/dt/events/delltechnologiesworld/2025/index.htm?msockid=21c662101c496b42343370ae1de86aaa#tab0=0&amp;accordion0" title="https://www.dell.com/en-us/dt/events/delltechnologiesworld/2025/index.htm?msockid=21c662101c496b42343370ae1de86aaa#tab0=0&amp;accordion0">https://www.dell.com/en-us/dt/events/delltechnologiesworld/2025/index.htm?msockid=21c662101c496b42343370ae1de86aaa#tab0=0&amp;accordion0</a>

DELL

NVDA

QCOM

Dell Technologies Says New PowerEdge Servers Can Be Customized With Up To 256 Nvidia Blackwell Ultra GPUs Per Dell IR7000 Rack; Plans To Support Nvidia Vera CPU; Plans To Support Nvidia Vera Rubin Platform With New Dell PowerEdge XE Server; Introduces Dell Pro Max Plus Laptop With Qualcomm AI 100 PC Inference Card

Dell Technologies Unveils Next Generation Enterprise AI Solutions With Nvidia; Introduces Air-Cooled Dell PowerEdge XE9780, XE9785 Servers & Liquid-Cooled Dell PowerEdge XE9780l, XE9785l Servers; New PowerEdge Servers Support Up To 192 Nvidia Blackwell Ultra GPUs With Direct To Chip Liquid Cooling

WIIM

Novo Nordisk shares are trading higher, rebounding after falling last week on a CEO departure announcement.

Morgan Stanley analyst Bob Huang maintains WR Berkley (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WRB#NYSE">WRB</a>) with a Equal-Weight and raises the price target from $63 to $75.

Morgan Stanley Maintains Equal-Weight on WR Berkley, Raises Price Target to $75

DOGZ

Dogness shares are trading higher after the company announced it entered into a share acquisition agreement to acquire a 19.5% equity interest in DITC

UnitedHealth shares are trading higher, rebounding following recent weakness.

Morgan Stanley analyst Bob Huang maintains Voya Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VOYA#NYSE">VOYA</a>) with a Overweight and raises the price target from $70 to $86.

VOYA

Morgan Stanley Maintains Overweight on Voya Financial, Raises Price Target to $86

Morgan Stanley analyst Adam Jonas maintains Visteon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VC#NASDAQ">VC</a>) with a Equal-Weight and lowers the price target from $95 to $90.

Comments

Babcock & Wilcox Enterprises, Inc. 8.125% Senior Notes due 2026

Babcock & Wilcox Enterprises, Inc. 8.125% Senior Notes due 2026 (BWSN) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO